| Bioactivity | PI3K/Akt/mTOR-IN-4 (compound 4r) is a potent PI3K/Akt/mTOR and tubulin polymerization inhibitor. PI3K/Akt/mTOR-IN-4 induce apoptosis and cell cycle arrest at G2/M phase. PI3K/Akt/mTOR-IN-4 decreases the expression of p-PI3K, p-Akt, and p-mTOR, β-tubulin[1]. |
| Invitro | PI3K/Akt/mTOR-IN-4 (compound 4r) (0-100 µM; 48 h) 显示出抗增殖活性，对 SiHa、HeLa、Ca Ski、LO2、HEK-293t 细胞的 IC50 值分别为 3.38、5.03、7.24、21.08、23.96 µM[1]。PI3K/Akt/mTOR-IN-4 (0-16 µM; 24 h) 诱导细胞凋亡和细胞周期停滞在 G2/M 期[1]。PI3K/Akt/mTOR-IN-4 (4, 8,16 µM；24 h) 以剂量依赖性方式降低 p-PI3K、p-Akt、p-mTOR 和 β-微管蛋白的表达[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PI3K/Akt/mTOR-IN-4 相关抗体: Cell Proliferation Assay[1] Cell Line: |
| In Vivo | PI3K/Akt/mTOR-IN-4 (0-400 μM; 0-96 h) 对斑马鱼胚胎没有毒性[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| Formula | C29H29FN4O3 |
| Molar Mass | 500.56 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Li SS, et al. Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K/Akt/mTOR pathway and tubulin inhibition. Eur J Med Chem. 2024 Apr 16;271:116425. |